Movement Disorders Center of Arizona
Welcome,         Profile    Billing    Logout  
 15 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Levine, Todd D
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
ENSURE-2, NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG
Multiple Sclerosis, Relapsing-Remitting
10/24
10/32
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Active, not recruiting
3
1512
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen
Alzheimer's Disease
12/25
10/26
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting
3
150
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05650567: Study of M5049 in DM and PM Participants (NEPTUNIA)

Recruiting
2
40
Europe, US, RoW
M5049 high dose, Enpatoran, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Dermatomyositis, Polymyositis
07/24
12/24
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Recruiting
2
48
Europe, Canada, US
ARGX-117, Placebo
argenx, argenx BV
Multifocal Motor Neuropathy (MMN)
11/25
10/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Recruiting
2
735
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
11/27
02/30
NCT04700722: Synuclein-One Study

Completed
N/A
428
US
Skin Biopsy
CND Life Sciences
Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
12/22
11/23
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
03/24
03/24
NCT05757206: The Syn-Sleep Study

Recruiting
N/A
80
US
Syn-One Test
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
08/25
08/25
Evidente, Virgilio
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Recruiting
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
10/24
02/25
Evidente, Danica
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT04797611: STEM-Parkinson's Disease

Recruiting
N/A
218
Europe, US
Non-invasive brainstem stimulation
Scion NeuroStim
Parkinson Disease, Parkinson's Disease and Parkinsonism
10/24
10/24
Phillips, Julia
DESTRICT, NCT06352073: Dupilumab for Eosinophilic Esophagitis With Severe Strictures

Not yet recruiting
4
30
US
Dupilumab, Dupilumab Pre-filled Syringe, Dupixent
University of North Carolina, Chapel Hill, Regeneron Pharmaceuticals, Sanofi
Eosinophilic Esophagitis, EoE
11/25
04/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27

Download Options